PitarresiPhD

I'm excited to share the lab’s new paper on PDAC-associated cachexia on bioRxiv today, led by star postdoc @Nikita2106 Pancreatic cancer cachexia is mediated by PTHrP-driven disruption of adipose de novo lipogenesis A 🧵 below, if you're interested... biorxiv.org/content/10.110…

New @iScience_CP paper by @NinaSteele17 @Pasca_Lab Primary and metastatic cellular landscapes in human #PancreaticCancer cell.com/iscience/fullt… Signatures of pancreatic cancer metastases associated T cells (exhausted), macrophages (complement pathway) and fibroblasts (UPP1 +).

Harvard, the nation’s oldest university, is facing off in court against the president today in a legal showdown, the outcome of which will reverberate across American higher education. wapo.st/45cvGKe

🧬We are thrilled to announce that Bin Liu, PhD (@BinLiu49077152) has joined the Gene Therapy Institute! Bin completed his PhD at University of Groningen and postdoc at @RTI_UMassChan. He is researching #GenomeEditing technologies to advance treatments for genetic diseases.

It finally happened! Congrats to @katcmurph and @peura_jessica on officially receiving their F31 fellowships! Very proud of both of you and could not be more deserving. NoA dreams still do come true.

Congrats to @katcmurph from our lab and @peura_jessica from @PitarresiLab on their great F31 application scores! Very proud of you both! Stay tuned for more to come from these rising stars!

Awesome new preprint from Christine Chio's group @Chiolaboratory on the role of Iron-regulating signaling in cancer cachexia! A new mechanism fueling adipose browning in cachexia.... biorxiv.org/content/10.110…

A special @jclinicalinvest series on #PancreaticCancer led by @BenStanger01 jci.org/articles/view/… jci.org/articles/view/… jci.org/articles/view/… jci.org/articles/view/… jci.org/articles/view/… Articles by @lauradelongwood @Muir_Lab @MaddipatiLab

50% OFF From One Cell: A Journey into Life's Origins and the Future of Medicine - through Aug 11! audiobooks.com/promotions/pro…

Congrats to Calvin in the lab for winning a travel award for the AAI Advanced Course! He's leading the tumor immunology efforts in the lab and I'm excited to see what he learns at the workshop! 🙏 Grateful to the AAI for supporting trainees during these tough financial times!

A jobs bonanza from @michiganstateu @HenryFordHealth hiring TEN cancer researchers! henryfordmsu.infoready4.com/#freeformCompe… Applicants focused on pancreas, brain, lung, breast, ovarian, prostate, and hematological cancers are especially encouraged to apply. Please share!

NOA!! 🚨 Congrats to @peura_jessica in the lab for getting her NCI F31 notice of award today!! 🚨 With the NIH slowdowns, this has been quite the journey, but I'm happy to see some NOAs coming through for the trainees! @UMassChan

New @AGA_Gastro study by Suresh Chari @MDAndersonNews: The 1st prospective study to estimate the risk of #PancreaticCancer in individuals with new onset diabetes based on glycemic criteria (G-NOD) shows profound impact of race/ethnicity, with Whites having highest risk (SIR 6.4)

🔥🚨New from #DattaLab @SylvesterCancer in Cancer Immunology Immunotherapy @SpringerNature: We report a cell-specific nanoengineering strategy to disrupt suppressive signaling from neutrophilic MDSCs in PDAC—without causing neutropenia. Paper: doi.org/10.1007/s00262… 🧵Thread👇1/

Online now: Conserved signals control self-organization and symmetry breaking of murine bilayered epithelia during development and regeneration dlvr.it/TLdxyz

Excited to present at this fantastic meeting!

1/🚨 New preprint out!🚨 We uncovered that #PI3K-driven wild-type RAS activation bypasses #KRAS inhibition in pancreatic adenocarcinoma (#PDAC) to drive #resistance. 🔑PI3K isn’t just a downstream RAS effector – it can be an upstream RAS regulator. 📄 biorxiv.org/content/10.110…

I am delighted to share our new study uncovering the role of innate immunity in regulating cell plasticity and reprograming of prostate tumor initiating cells published in @NatureCancer . Congrats @ChenJiang919 and @yura__song , the first authors, nature.com/articles/s4301…

Now in @Cancer_Cell our group reports the development of a first-in-class EGFR-directed KRAS G12V selective inhibitor. KRAS G12V mutations are the 2nd most common KRAS mutation in cancer, and there are still no approved inhibitors in the clinic. We address two major challenges…

🤩Super excited our branched #PancreaticCancer #Organoids to capture tumour heterogeneity made it on the cover of @natBME 🙏🏼nature.com/natbiomedeng/v… @TU_Muenchen @DKTK_ @TUMKlinikum @arispapargyriou @LabReichert

A US judge has ordered hundreds of terminated research projects at the NIH to be reinstated, calling the processes that led to their cancellation “bereft of reasoning”. go.nature.com/3SSKmrh